Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:PKI

Revvity (PKI) Stock Price, News & Analysis

Revvity logo

About Revvity Stock (NYSE:PKI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$115.24
$137.11
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
851,117 shs
Market Capitalization
$14.57 billion
P/E Ratio
15.01
Dividend Yield
0.24%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

Revvity, Inc. (RVTY)
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t. With 40+ years of market modeling, he says Musk’s move wasn’t about efficiency — it was a signal. And what’s coming next could divide the market into winners and losers faster than anyone expects. Watch this urgent video briefing now.
Revvity Inc PKI
See More Headlines

PKI Stock Analysis - Frequently Asked Questions

Revvity, Inc. (NYSE:PKI) released its quarterly earnings data on Thursday, May, 11th. The medical research company reported $1.01 EPS for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to the consensus estimate of $686.30 million. Revvity had a net margin of 28.94% and a trailing twelve-month return on equity of 11.17%.

Revvity's Board of Directors approved a stock repurchase plan on Thursday, May 11th 2023, which permits the company to buy back $600,000,000 in shares, according to EventVestor. This means that the company could buy up to 4.1% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board of directors believes its shares are undervalued.

Revvity subsidiaries include these companies: BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and more.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Visa (V), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/11/2023
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:PKI
Employees
16,700
Year Founded
1937

Profitability

Trailing P/E Ratio
15.01
Forward P/E Ratio
N/A
P/E Growth
0.5
Net Income
$569.18 million
Pretax Margin
13.81%

Debt

Sales & Book Value

Annual Sales
$3.31 billion
Price / Cash Flow
9.88
Book Value
$58.49 per share
Price / Book
N/A

Miscellaneous

Free Float
125,755,000
Market Cap
$14.57 billion
Optionable
Optionable
Beta
1.10

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NYSE:PKI) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners